STEAP2 Recombinant Monoclonal Antibody

STEAP2, also known as six-transmembrane epithelial antigen of prostate 2, is a metalloreductase that has garnered significant attention in cancer research due to its marked upregulation in metastatic prostate cancer. This membrane protein plays a role in cellular iron and copper homeostasis and has been identified as a potential biomarker and therapeutic target, making it a compelling focus for researchers investigating prostate cancer progression and metastatic mechanisms.

This recombinant monoclonal antibody, clone 6B3, offers the reproducibility and consistency that demanding research applications require. Produced using recombinant technology with a defined sequence, this antibody eliminates the lot-to-lot variability that can compromise longitudinal studies and multi-site collaborations. The human IgG1 isotype format, combined with affinity chromatography purification, ensures high specificity for your target while minimizing background interference.

Validation studies demonstrate reliable performance in flow cytometry applications, with recommended dilutions ranging from 1:50 to 1:200. Testing in PC-3 cells, a well-established human prostate cancer cell line, confirmed specific detection of STEAP2 following fixation and permeabilization, showing clear separation from isotype control. This intracellular staining protocol provides a validated starting point for researchers examining STEAP2 expression patterns in prostate cancer models. The antibody is also validated for ELISA, offering flexibility across different experimental workflows.

Supplied in a stabilized liquid format containing glycerol and PBS with Proclin 300 preservative, this antibody is ready for immediate use in your cancer research applications. Whether you are profiling STEAP2 expression across tumor samples or investigating its role in metastatic progression, this recombinant antibody delivers the performance and consistency your research demands.